drugset / Trial / NCT02701673
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of belinostat that can be given in combination with azacitidine, gemcitabine, busulfan, and melphalan to patients who are scheduled to have a stem cell transplant. If you have diffuse large B-cell lymphoma (DLBCL), you will also receive rituximab. Researchers also want to learn about the safety and effectiveness of this combination.
Timeline
- Start
- 2016-06
- Primary completion
- 2019-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 15 mg/m2 | Intravenous |
| Subject | Belinostat | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Busulfan | Small molecule | 32 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 60 mg/m2 | Intravenous |
| Background | Caphosol | Other / unclassified | 30 ml | Oral |
| Background | Glutamine | Other / unclassified | 15 g | Oral |
| Background | Pyridoxine | Unknown | 100 mg | Intravenous |